TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum

Reuters

Feb 06

TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum

TG Therapeutics Inc. announced the presentation of new data on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in San Diego, California. The data include updates from the ENABLE real-world study evaluating patients with relapsing multiple sclerosis (RMS) on BRIUMVI, as well as the study designs for the Phase 2 ULTIMATE KIDS I and Phase 3 ULTIMATE KIDS II trials, which assess ublituximab in children and adolescents with RMS. Additional presentations featured results from a multi-protein biomarker test in participants treated with ublituximab from the ENHANCE study. All presentations are available through the ACTRIMS ePoster gallery and on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650147-en) on February 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609555593"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609555593\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609555593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609555593","market":"fut","top_or_hot":-1,"title":"TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics Inc.</a> announced the presentation of new data on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in San Diego, California. The data include updates from the ENABLE real-world study evaluating patients with relapsing multiple sclerosis (RMS) on BRIUMVI, as well as the study designs for the Phase 2 ULTIMATE KIDS I and Phase 3 ULTIMATE KIDS II trials, which assess ublituximab in children and adolescents with RMS. Additional presentations featured results from a multi-protein biomarker test in participants treated with ublituximab from the ENHANCE study. All presentations are available through the ACTRIMS ePoster gallery and on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650147-en) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics Inc.</a> announced the presentation of new data on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in San Diego, California. The data include updates from the ENABLE real-world study evaluating patients with relapsing multiple sclerosis (RMS) on BRIUMVI, as well as the study designs for the Phase 2 ULTIMATE KIDS I and Phase 3 ULTIMATE KIDS II trials, which assess ublituximab in children and adolescents with RMS. Additional presentations featured results from a multi-protein biomarker test in participants treated with ublituximab from the ENHANCE study. All presentations are available through the ACTRIMS ePoster gallery and on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650147-en) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL84khrt:1","article_id":"2609555593","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609555593","pubTimestamp":1770381035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TG Therapeutics Inc. announced the presentation of new data on BRIUMVI  in multiple sclerosis at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis  annual forum in San Diego, California. The data include updates from the ENABLE real-world study evaluating patients with relapsing multiple sclerosis  on BRIUMVI, as well as the study designs for the Phase 2 ULTIMATE KIDS I and Phase 3 ULTIMATE KIDS II trials, which assess ublituximab in children and adolescents with RMS. Additional presentations featured results from a multi-protein biomarker test in participants treated with ublituximab from the ENHANCE study. All presentations are available through the ACTRIMS ePoster gallery and on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","TGTX":"TG Therapeutics Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4139":"生物科技","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"TG Therapeutics在ACTRIMS论坛上公布了针对多发性硬化症的新BRIUMVI数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":0.9,"NDAQ":0.9},"content_text":"TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum\n    \n\nTG Therapeutics Inc. announced the presentation of new data on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in San Diego, California. The data include updates from the ENABLE real-world study evaluating patients with relapsing multiple sclerosis (RMS) on BRIUMVI, as well as the study designs for the Phase 2 ULTIMATE KIDS I and Phase 3 ULTIMATE KIDS II trials, which assess ublituximab in children and adolescents with RMS. Additional presentations featured results from a multi-protein biomarker test in participants treated with ublituximab from the ENHANCE study. All presentations are available through the ACTRIMS ePoster gallery and on the company's website.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650147-en) on February 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}